Clinical trial · no report yet · Phase 1/Phase 2

TiNivo trial (tivozanib): what clinicians have said so far

Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC

NCT03136627 ↗
Completed
AVEO Pharmaceuticals, Inc.
Standard size, estimated: 151–300 verified statements

We haven't built an HCP commentary report on TiNivo (tivozanib plus nivolumab in metastatic renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on TiNivo so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
9 posts on X
4 YouTube videos
2 podcast episodes

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma
Phase: Phase 1/Phase 2
Status: Completed
Conditions: Carcinoma, Renal Cell
Interventions: Tivozanib; Nivolumab
Arms: Tivozanib (AV-951) plus Nivolumab · Experimental
Enrollment: 28
Primary outcomes: Maximum Tolerated Dose (MTD) of tivozanib administered orally in combination with Nivolumab in subjects with advanced renal cell carcinoma.
Sponsor: AVEO Pharmaceuticals, Inc. with Bristol-Myers Squibb
Start: Mar 22, 2017
Primary completion: Dec 21, 2017
Results posted: No
Registry record: NCT03136627 · updated Dec 6, 2021

Publications

linked from the registry

Albiges L, Barthelemy P, Gross-Goupil M, Negrier S, Needle MN, Escudier B. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2021 Jan;32(1):97-102. doi: 10.1016/j.annonc.2020.09.021. Epub 2020 Sep 30. PubMed 33010459

Get this report

Standard

Report, built on orderBuilt within 24 hours of confirming your order: $1,250

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on TiNivo so far

Reports on the same drug or indication

The trial

Publications